The Latest
-
Andrew Harnik via Getty Images
Novo, Lilly cut deal with Trump to lower prices of obesity drugs
The agreement will make Wegovy and Zepbound available to some Medicare enrollees for $245 per month, and starter doses of pill versions, once approved, for $149 monthly.
-
Getty Images
Sponsored by ZelisHow flexible technology is redefining healthcare compliance
Composable tech is transforming healthcare—faster compliance, smarter savings, scalable growth.
-
Alamy
Cigna’s new chief medical officer starts as other execs depart the company
Dr. Amy Flaster, Cigna Healthcare’s chief medical officer since last year, is stepping up as CMO of the whole enterprise. At the same time, Cigna’s chief health officer and a business improvement executive are hitting the road.
-
Spencer Platt via Getty Images
Humana confident in Medicare Advantage growth despite plan generosity muddling margin recovery
The Medicare giant likes what it’s seen in the first two weeks of open enrollment. But there are steps it can take if membership growth starts getting out of hand, executives said.
-
Getty Images
Most healthcare organizations face significant financial, operational impact from cyber threats: survey
More than 70% reported moderate to severe financial effects from an incident in the past two years, while nearly 60% cited clinical impacts, according to the report by Ernst & Young and Klas Research.
-
Permission granted by Amwell
Amwell mulls divestitures
The company is considering selling assets that could be more easily separated from the rest of the business without creating challenges for customers, executives said on a third quarter earnings call.
-
Getty Images
Prospect clashes with Rhode Island regulators over plans to close two hospitals
Prospect Medical Holdings is seeking approval from a bankruptcy court to close its hospitals in Rhode Island. Regulators and the new buyer say Prospect needs to follow through with a deal to sell them.
-
Alamy
UnitedHealthcare pays Optum doctors more than other doctors: study
Researchers said the results suggest UnitedHealth may be sidestepping government rules meant to keep a lid on exorbitant payer profits. UnitedHealth said the study was “flat-out wrong.”
-
Permission granted by Aspen Institute
Legislators object to proposed CMS payment changes for diabetes tech
In a letter to CMS Administrator Dr. Mehmet Oz, diabetes caucus leaders raised concerns that the agency’s proposals will reduce access to glucose monitors and insulin pumps.
-
Getty Images
Health system execs are prioritizing AI, digital tech to overhaul care delivery: survey
Leaders are worried some of the sector’s persistent challenges — like finance pressures and worker burnout — could worsen over the next five years without significant changes, according to a survey by Chartis.
-
Getty Images
Federal ACA enrollment kicks off without action on subsidies
Millions of Americans are facing steep price hikes for Affordable Care Act coverage while Congress dithers over the issue. Experts say there’s not as much time to act as legislators may believe.
-
Al Drago via Getty Images
Health groups urge passage of bill to ease Medicare pay cuts for tests
More than 30 organizations, including AdvaMed and the American Clinical Laboratory Association, are pushing for a permanent legislative solution to stop looming Medicare payment cuts for diagnostic tests.
-
Getty Images
Medicare finalizes controversial cut to specialty care next year
The CMS finalized the Medicare physician fee schedule for 2026 on Friday, one day before the statutory deadline. It includes an overall payment hike and a few policies that are deeply unpopular with specialists.
Updated Nov. 4, 2025 -
Getty Images
CHS inks deal to sell stake in Tennessee hospital to VUMC
The $600 million deal was foreshadowed during the company’s third quarter earnings call this month, when CEO Kevin Hammons said more hospital sales were in the works.
-
Getty Images
HRSA approves 340B rebate models to hospitals’ chagrin
Drugs that will be subject to rebates in 340B next year include Bristol Myers Squibb’s Eliquis, Johnson & Johnson’s Stelara and Novo Nordisk’s Novolog.
-
Getty Images
Few health systems report significant ROI from virtual care: survey
Fewer than 30% of health system leaders said they earned a significant return on investment from virtual care offerings, according to the report by Sage Growth Partners.
-
IPGGutenbergUKLtd via Getty Images
OpinionNew CBO report confirms 340B’s ballooning costs. Congress must act.
Former Congressional Budget Office Director Dan Crippen argues the 340B discount program is overdue for reform.
-
Alamy
Cigna’s 2026 pharmacy profits could be dampened by transition to rebate-free model
Overall, Cigna expects earnings to grow next year after posting a solid third quarter. But investments in a new PBM model and discounted contracts for some big clients could lower Express Scripts’ profitability, executives said.
-
Courtesy of Summa Health
Summa Health CEO to step down at end of 2025
Dr. Cliff Deveny announced the transition less than a month after General Catalyst finalized its $515 million acquisition of Summa.
-
Courtesy of Teladoc
Teladoc expands insurance coverage at mental health unit BetterHelp
Executives expect insurance coverage availability will be “largely national” by the end of 2026. The initiative is important for Teladoc to turn around financial performance for the segment, which has seen earnings and revenue decline.
-
Joe Raedle via Getty Images
CVS hikes 2025 guidance despite goodwill impairment charge on healthcare delivery
The healthcare giant beat Wall Street expectations in the third quarter, but reported a net loss after recording a $5.7 billion charge linked primarily to decelerating clinic growth at Oak Street Health.
-
Getty Images
Tenet pledges more money for high-acuity growth in 2025
The hospital operator will invest more in organic hospital growth and high-acuity service lines as it sees strong demand for services.
-
Alamy
Centene posts $6.6B loss on massive value writedown
The goodwill impairment charge is meant to realign Centene’s value on its own books with its value in the market, which has plummeted this year. Still, Centene upped its earnings outlook for 2025.
-
Anna Moneymaker via Getty Images
FDA, aiming to lower drug costs, moves to speed approval of biosimilars
The agency will no longer require studies comparing copycat biologics to their branded counterparts, which could help developers bring them to market more quickly and cheaply.
-
Courtesy of UnitedHealth Group
UnitedHealth maps path back to Wall Street’s good graces
The healthcare giant beat Wall Street expectations in the third quarter and raised its 2025 earnings guidance, albeit modestly.
-
Getty Images
Voters blame insurers for medical debt: poll
More than 60% of respondents said insurance companies are most at fault for medical debt, compared with just 9% who blamed hospitals, according to a survey by nonprofit Undue Medical Debt.
